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Effect of bupivacaine lozenges on oral mucositis
pain: a randomized controlled multicenter phase
II study
Stine Mogensena,*, Charlotte Treldala, Claus A. Kristensenb, Jens Bentzenc, Louise Lawson-Smitha,
Janne Petersena,d, Ove Andersena
Abstract
Introduction: A nonblinded parallel-group randomized controlled study investigated the efficacy and tolerability of repeated
administration of a bupivacaine lozenge (25 mg) as pain management for oral mucositis pain in head and neck cancer patients as
add-on to standard systemic pain management.
Objective: The primary end point was the difference between the intervention group (Lozenge group) and the Control group in daily
mean pain scores in the oral cavity or pharynx (whichever was higher).
Method: Fifty patients from2 hospitals in Denmarkwere randomized 1:1 to 7 days of treatment with bupivacaine lozenges (taken up
to every 2 hours) plus standard pain treatment minus topical lidocaine (Lozenge group) or standard pain treatment including topical
lidocaine (Control group). The efficacy analysis included 38 patients, as 12 patients were excluded because of changes in study
design and missing data.
Results:Meanpain in the oral cavity or pharynx (whicheverwas higher) was significantly lower 60minutes after taking lozenges (35mm [n
5 22]) than for the Control group (51 mm [n 5 16]) (difference between groups 216 mm, 95% confidence interval: 226 to 26, P 5
0.0032). Pain in the oral cavity was also significantly lower in the Lozenge group (18 mm) vs the Control group (36 mm, P 5 0.0002).
Pharyngeal mucositis pain did not differ significantly (37mm [Lozenge group] vs 48mm [Control group],P5 0.0630). No serious adverse
events were reported.
Conclusion: These results show that the bupivacaine lozenge as an add-on to standard pain treatment had a clinically significant
pain-relieving effect in patients with oral mucositis.
ClinicalTrials.gov: NCT02252926.
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1. Introduction
Eighty to 100% of adult patients who undergo radiotherapy with
or without concurrent chemotherapy for head and neck cancer
will experience oral mucositis as a painful side effect of their
cancer treatment.1,4,9,16 Oral mucositis is painful damage to the
mucosa in the oral cavity and the pharynx and is associated with
vital oral dysfunction such as swallowing problems.3 It has been
identified by patients as the most severe side effect associated
with cancer treatment in head and neck cancer patients as it
induces severe problems with eating, drinking, and speaking.1,3
For patients with mild to moderate oral or pharyngeal mucositis
pain, it would be advantageous to be able to manage pain locally
rather thansystemically, as local treatmentshave fewer sideeffects.15
Various lidocaine preparations, in the form of sprays or viscous
solutions, are currently used for local anesthesia of the oral cavity and
pharynx,15 but the effect is short lasting and the formulations are not
very patient friendly because of unpleasant taste and texture. Such
preparations are understood to be of limited, if any, effect in
management of pain in patients with oral mucositis.16 Paracetamol,
opioids, and gamma-aminobutyric acid analogs are currently the
most frequently used systemic analgesic treatments, but a few data
on the most beneficial analgesic therapy are available.1 At present,
no effective pain treatment without substantial side effects exists
for patients with severe oral mucositis pain, and in many patients
treated with high-dose opioids there is a lack of sufficient pain relief.8
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The lack of adequate pain management for oral
mucositis–associated pain has led researchers to conduct
numerous studies testing various active compounds in many
different formulations in the search for new pain prevention and
management options,15 with limited, if any, success. Two phase I
studies, each conducted in 10 healthy subjects and 10 patients
with head and neck cancer have investigated the safety of a loz-
enge containing 25 mg of the local anesthetic bupivacaine. They
showed no signs of toxic plasma concentrations or risk of aspi-
ration.10,11 Moreover, a pilot study in which a single dose of the
lozenge was administered to patients with head and neck cancer
showed a strong, long-lasting pain-relieving effect, with a mean
duration of maximum pain relief in the oral cavity of 42 minutes
and a significant pain relief even after 180 minutes.12 Lidocaine
viscous solution has been reported to have a duration of 15 to 20
minutes.6
The aim of this nonblinded parallel-group randomized con-
trolled study was to investigate the efficacy and tolerability of
repeated administration of a bupivacaine lozenge (25 mg) as pain
management for oral or pharyngealmucositis pain in patients with
head and neck cancer as an add-on to standard systemic pain
management. The primary end point was pain in the oral cavity or
pharynx (whichever was higher), scored on a 0 to 100 mm visual
analog scale (VAS) every 2 hours (Control group) or 60 minutes
after taking a lozenge (Lozenge group).
2. Methods
2.1. Ethics
The study protocol and amendments were approved by the
National Committee on Health Research Ethics (H-6-2014-034)
and the Danish Health and Medicines Authority (EudraCT 2014-
002346-42). The study was registered at the Danish Data
Protection Agency (AHH-2014-034) and ClinicalTrials.gov
(NCT02252926). The study was conducted at 2 sites in Denmark
in accordance with the ethical principles that have their origins in
the Declaration of Helsinki. The Good Clinical Practice (GCP) unit
at Copenhagen University Hospitals monitored the study at both
sites. A written declaration of informed consent was obtained
from patients before their inclusion in the study.
2.2. Participants
Head and neck cancer outpatients from the Departments of
Oncology at Copenhagen University Hospital, Rigshospitalet and
Copenhagen University Hospital, Herlev were included in this
randomized controlled study. The inclusion criteria in the original
protocol were diagnosis of head and neck cancer, age between
18 and 80 years, ability to speak and read Danish, ability to use
electronic devices such as a tablet or smartphone, and ability to
provide written informed consent. In an amendment to the
original protocol (amendment 2.1) that was introduced after 7
patients had been randomized, oral- or pharyngeal mucositis
pain of$40mmon a 0 to 100mmVASwas added as an inclusion
criterion to ensure that patients had pain in either the oral cavity or
pharynx when they were randomized. In a subsequent amend-
ment (amendment 5), the ability to use electronic devices was
removed and a paper diary was introduced instead, because the
initial patients had problems registering pain and pain medication
intake in the electronic diaries. Five patients (3 in the Lozenge
group and 2 in the Control group) used the electronic diary and
the remaining patients used the paper diary. The exclusion criteria
in the original protocol were need for pain treatment with
morphine before the start of radiotherapy, known allergy to
bupivacaine or other local anesthetics of the amide type,
pregnancy, and breastfeeding. The exclusion criterion related to
morphine was removed in amendment 2.1.
2.3. Study medicine
The study medicine was manufactured by direct compression at
the Capital Region Pharmacy, Denmark. Each lozenge contained
28.16mg of bupivacaine hydrochloride, which corresponds to 25
mg of bupivacaine, and licorice powder and aspartame to mask
the bitter taste of bupivacaine. The lozenge also contained
mannitol, talc, and magnesium stearate as fillers.
2.4. Design
This was a nonblinded parallel-group phase II randomized
controlled study. Patients with head and neck cancer who fulfilled
the inclusion criteria and none of the exclusion criteria were
included in the study by a study nurse or pharmacist and thereafter
had daily prerandomization screening visits at the hospital (Fig. 1).
At these visits, oralmucositis andpain in theoral cavity and pharynx
were scored and pain medication use was registered. When their
oral mucositis pain could not be relieved by paracetamol treatment
(original protocol) or their VAS score for oral- or pharyngeal
mucositis pain reached $40 mm (after amendment 2.1), patients
were randomized to either standard pain management plus
Figure 1. Overview of study visits after implementation of protocol amendment 2.1. *Day 8 or 9. VAS, visual analog scale.
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repeated administration of bupivacaine lozenges (Lozenge group)
or standard pain treatment plus per need topical lidocaine and
benzydamine mouthwash (Control group) for 7 days. Standard
pain treatment was systemic analgesics (eg, morphine and
paracetamol) as needed. The patients in the Lozenge group did
not receive lidocaine or benzydamine during the study; otherwise
their standard pain treatment was the same as for the Control
group. During the 7-day treatment period, the patients had 6 daily
study visits at the hospital in conjunction with their radiotherapy
(therewas no study visit on the 1 day in theweekwhen they did not
receive radiotherapy) (Fig. 1). On study day8 or 9, therewas an end
of study visit.
2.5. Study procedures
According to the original protocol, patients with head and neck
cancer were assessed for pain in the oral cavity and pharynx on
a daily basis from their first day of radiotherapy. After amendment
2.1 was introduced, patients were screened daily for oral- and
pharyngeal mucositis pain from the first day of their third week of 6
scheduled weeks of radiotherapy.
From their inclusion in the study to the end of study visit,
patients scored their oral- and pharyngeal mucositis pain
separately from 0 mm (no pain) to 100 mm (worst conceivable
pain) on a VAS. During the prerandomization screening period,
patients scored oral- and pharyngeal mucositis pain at each
hospital visit. After randomization, the patients in the Lozenge
group assessed pain in the oral cavity and the pharynx before and
60 minutes after administration of a lozenge and recorded their
values in their patient diary (electronic or paper); patients in the
Control group assessed pain in the oral cavity and the pharynx
separately on the VAS every 2 hours when awake. Pain
assessments were performed at home on each of the 7 days of
the treatment period and at the hospital at the end of study visit. At
each study visit, patients in the Lozenge group were given study
medicine for the next day (on the day before their day without
radiotherapy, study medicine for 2 days was supplied). Patients
were informed to take lozenges every 2 hours during waking
hours up to amaximumof 8 lozenges per day. Each time a patient
entered a pain score in the electronic diary, the time of the scoring
was recorded automatically. In the paper diary, the patient noted
both the time of administration of lozenges as well as the time of
pain scoring. Pain scores were also entered in the diaries by the
patients in both groups each morning (before they took
a bupivacaine lozenge, in the case of the Lozenge group). Pain
scores were recorded separately for the oral cavity and for the
pharynx in both groups.
Along with pain scores and the time of scoring, the patients in
both groups were asked to record their use of pain therapeutic
drugs during the 7-day treatment period. For all pain therapeutic
drugs, including the lozenges, the name and dose of the drug and
time of administration were recorded. Pain medication use during
the prerandomization screening period was registered by a study
nurse or pharmacist.
Oral mucositis was assessed using the World Health
Organization scale for oral mucositis, which is based on
subjective and objective symptoms,14 where 0 5 no symptoms;
1 5 erythema and/or soreness, no ulcers; 2 5 erythema and
ulcers, the patient can swallow solid food; 35 ulcers andmarked
erythema, the patient cannot swallow solid food; and 4 5 oral
mucositis to a degree that makes normal nutrition impossible.
Scoring was performed by a study nurse or pharmacist who was
trained in assessing mucositis. The assessment was conducted
during each visit from inclusion to the end of study visit.
Adverse events (AEs) were registered at study visits on days 1
to 7 and at the end of study visit. Blood samples were drawn from
10 patients in the Lozenge group to assess whether the
bupivacaine concentrations in plasma would accumulate after
multiple administrations of the lozenges over 7 days. Method and
results of these data on the 10 patients are reported in the study
by Mogensen et al., 2017.10
2.6. Randomization
Patients were randomized to either the Lozenge group or the
Control group at a ratio of 1:1. The randomization was performed
by an independent statistician at PCG Clinical Services AB, who
created a computer-generated randomization schedule with
randomly varying block sizes to avoid predictability in the
assignment of therapy. The randomization schedule was
uploaded to the web-based electronic database system Viedoc,
supplied by the Contract Research Organization PCG Solutions
AB, which assigned the patients to either the Lozenge group or
the Control group.
2.7. Outcomes
2.7.1. Primary end point
The primary end point was the difference between the 2 groups in
daily mean pain scores measured on a VAS. For the Lozenge
group, the mean daily pain score for each patient was calculated
as the mean of the pain scores recorded 60 minutes after
administration of each bupivacaine lozenge. The window for pain
registration 60 minutes after taking a lozenge was 615 minutes.
For the Control group, the mean daily pain score for each patient
was calculated as the mean of the pain scores recorded every 2
hours. For each assessment (time point), the highest of the scores
for the oral cavity and pharynx was used in the calculation of the
mean daily pain score for each patient in both groups.
2.7.2. Secondary end points
The secondary end points included mean pain (VAS) for the oral
cavity and the pharynx, scored separately 60 minutes after
administration of a bupivacaine lozenge (Lozenge group) or every
2 hours (Control group); andmeanpain (VAS) for the oral cavity and
the pharynx, scored separately and as the highest of the values for
these 2 anatomical sites immediately before administration of
a bupivacaine lozenge (with the exception of the first lozenge of the
day) (Lozenge group) or every 2 hours (Control group). For the
Lozenge group, the difference between the first pain score (VAS) in
the morning (before administration of the first bupivacaine lozenge
of the day) and the pain score (VAS) 60 minutes after the first
bupivacaine lozenge of the day was separately assessed for the
oral cavity and pharynx. The patients registered their use of
concomitant pain medication daily from randomization.
2.8. Statistical methods
2.8.1. Determination of sample size
The power calculation was based on pain scores (VAS) from 10
patients with head and neck cancer from a previous study12 and
was based on a paired t test. With a minimum clinically relevant
difference in pain between the 2 groups of 15 mm, a mean
baseline pain of 57 mm, an SD of 15 mm, 80% power, and
a significance level of 0.05; it resulted in a sample size of 32
patients completing the study. Approximately 40 patients were
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scheduled to be randomized to take account of an estimated
dropout rate of 20%.
2.8.2. Efficacy evaluation
The objective of the statistical analysis of the primary end point
was to determine whether there was a difference in mean pain
scores between the 2 groups. This was performed by estimating
a mixed model for repeated measures. Treatment day was
regarded as the time variable. The response variable was mean
daily pain (VAS) for each patient. For each time point with a pain
recording, the higher of the recorded pain scores for the oral
cavity and pharynx was used. Treatment group and oral
mucositis scores were included as categorical independent
variables. Baseline pain score (the last VAS score before
randomization, recorded on day 1 of the treatment period) was
included as a continuous independent variable. In the analysis of
the primary end point, the higher of the baseline pain scores for
the oral cavity and pharynx was used as the baseline for each
patient. An interaction effect between treatment day and
treatment group was also included in the model. Mixed model
for repeated measures models were also calculated for the
secondary end points. These models had the same correlation
structure as that used in the analysis of the primary end point.
Data for percentage of patients using opioids were analyzed by x2
test. Results are given as estimate of parameters as a mean
difference with a 95% confidence interval (CI).
All statistical analyses, except for the analysis of percentage of
patients using opioids, were performed using SAS (Version 9.4,
SAS Institute Inc, Cary, NC). All tests were 2 sided and were
performed at the 5% significance level.
3. Results
3.1. Subjects
A total of 70 patients with head and neck cancer were screened
from October 2014 to November 2015 at the Departments of
Oncology at 2 Danish university hospitals. The last patient
completed the study in December 2015. Seven patients were
randomized under the original protocol, and 43 patients were
randomized after approval of amendment 2.1. Twenty-six
patients were randomized to the Lozenge group and 24 to the
Control group. The 7 patients included under the original protocol
were excluded from the efficacy analysis as their baseline pain
scores were ,40 mm.
A total of 38 patients were included in the efficacy analysis (Fig.
2). Of these, 22were from the Lozenge group and 16were from the
Control group. The median number of pain registrations (VAS
scores) per day from baseline to day 7 was 7.5 (range: 0–14) in the
Lozenge group and 6 (range: 0–8) in the Control group. De-
mographic data, cancer diagnosis, and baseline pain scores for the
patients are shown in Table 1. There were no major differences in
baseline data between the 2 groups, although there was a slight
majority of ex-smokers, patients with oral cancer, and patients with
oral mucositis score 0 at baseline in the lozenge group.
3.2. Primary end point
Mean pain in the oral cavity or pharynx (whichever was higher),
scored 60minutes after administration of a bupivacaine lozenge in
the Lozenge group and every 2 hours in theControl group, showed
a significant difference between groups in favor of the lozenge.
Meanpainwas35mm inpatients in the Lozenge groupand51mm
in patients in the Control group (difference between groups 2
16 mm, 95% CI: 226 to 26, P 5 0.0032) (Table 2 and Fig. 3).
3.3. Secondary end points
When pain scores for the oral cavity and pharynx were analyzed
separately, the Lozenge group showed superior results compared
with theControl group (Table 2,Fig. 4, andFig. 5).Whenpain for the
Lozenge group was measured as the mean pain score 60 minutes
after lozenge administration, the intensity of oral cavity pain was
significantly lower in the Lozenge group than in the Control group
(mean difference: 218 mm, 95% CI: 227 to 210, P 5 0.0002).
Figure 2. Study flow chart. VAS, visual analog scale.
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Pharyngeal mucositis pain did not show a significant difference
between groups (P5 0.0630) (Table 2, Fig. 4).
When pain for the Lozenge group was measured as the mean
pain score immediately before the next lozenge, pain was
significantly lower in the Lozenge group than in the Control group
for both the oral cavity (mean difference: 215 mm, 95% CI:223
to27, P5 0.0004) and the pharynx (mean difference:211 mm,
95% CI: 222 to 0, P 5 0.0452) (Table 2, Fig. 5).
3.4. Patient-reported pain medication use
Pain medications used by patients, in both groups, during the
7-day treatment period included paracetamol, ibuprofen, and
opioids. Of the 23 patients assigned to the Lozenge group after
amendment 2.1, 22 used the lozenges, and the median
number of bupivacaine lozenges consumed per day was 4
(range: 0–7); 1 patient did not take any lozenges and
was excluded from the efficacy analysis (Fig. 2). Eight patients
in the Control group (50%) used topical lidocaine after
randomization.
3.5. Adverse events
In total, 5 AEs were reported in 3 of the 25 patients (12.0%) who
consumed at least 1 bupivacaine lozenge. All AEs were assessed
as mild and were categorized as follows: dysphagia (1),
odynophagia (1), hyperalgesia (2), and salivary hypersecretion
(1). The 2 cases of hyperalgesia were assessed as related to the
bupivacaine lozenge; the other 3 AEs were assessed as possibly
related to the bupivacaine lozenge. The 2 patients with hyper-
algesia in the Lozenge group withdrew because of AEs. One AE
(malaise) was reported in the control group. No serious AEs were
reported in the study.
4. Discussion
Our aim of this nonblinded parallel-group randomized controlled
study to test the efficacy and tolerability of repeated administra-
tion of a bupivacaine lozenge (25 mg), as an add-on to standard
systemic pain management was fulfilled. The results showed that
the pain in the Lozenge group 60 minutes after intake of a 25 mg
bupivacaine lozenge was significantly lower than that experi-
enced by the Control group. Moreover, the pain-relieving effect of
the lozengewas sustained during a relevant period because there
was a statistically and clinically significant reduction in pain in the
Lozenge group compared with the Control group immediately
before intake of the next lozenge.
Pain scores for the oral cavity were significantly lower 60
minutes after lozenge administration in the Lozenge group than
theywere in theControl group.Many patients had pain in both the
oral cavity and pharynx, but pain was often lower or absent in 1 of
these 2 sites. The fact that all randomized patients included in the
efficacy analysis had a minimum baseline pain score of 40 mm in
the oral cavity and/or pharynx indicates inadequate standard pain
management, as all patients were medicated with one or more
systemic drugs at randomization. It was therefore surprising that
patients in the Lozenge group only consumed amedian of 4 of the
8 bupivacaine lozenges they were permitted to take each day.
Possible explanations for the lower than anticipated consumption
include that the lozenges may have had a prolonged pain-
relieving effect, as shown previously.12 There is an immediate
Table 1





Age, median (range), y 63.0 (50–79) 57.5 (51–72)
Weight, median (range), kg 77 (57–107) 80 (64–123)
Sex, male 21 (95.5%) 13 (81.3%)
Smoking history
Current smoker 6 (27.3%) 1 (6.3%)
Ex-smoker 12 (54.5%) 13 (81.3%)
Never smoked 4 (18.2%) 2 (12.5%)
Cancer diagnosis
Oral cancer 4 (18.2%) 0 (0.0%)
Pharyngeal cancer* 14 (63.6%) 13 (81.3%)
Laryngeal cancer 4 (18.2%) 2 (12.5%)
Unknown primary tumor 0 (0.0%) 1 (6.3%)
Cancer treatment
Radiotherapy 22 (100.0%) 16 (100.0%)
Concurrent chemotherapy 13 (59.1%) 9 (56.3%)
Oral mucositis score at baseline
0 9 (40.9%) 4 (25.0%)
1–2 11 (50.0%) 10 (62.5%)
3 2 (9.1%) 2 (12.5%)
4 0 (0.0%) 0 (0.0%)
Baseline pain (mm, VAS)
Higher of the pain scores for the oral
cavity and pharynx, mean (SD, range)
58 (17.5, 40–99) 50 (9.8, 40–74)
Oral cavity, mean (SD, range) 35 (23.6, 0–76) 31 (20.8, 0–66)
Pharynx, mean (SD, range) 55 (21.8, 6–99) 48 (11.5,
25–74)
Data are presented as n (%), unless otherwise indicated.
* Pharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, or nasopharyngeal cancer.
VAS, visual analog scale.
Table 2
Pain measurements.
Lozenge group, n 5 22 Control group, n 5 16 Difference P
60 min after lozenge administration*
Worst pain on VAS†, mean (95% CI) 35 mm (28–43) 51 mm (43–84) 216 mm (226 to 26) 0.0032
Oral mucositis pain on VAS, mean (95% CI) 18 mm (12–24) 36 mm (30–43) 218 mm (227 to 210) 0.0002
Pharyngeal mucositis pain on VAS, mean
(95% CI)
37 mm (28–45) 48 mm (39–57) 212 mm‡ (224 to 1) 0.0630
Immediately before lozenge administration*
Worst pain on VAS†, mean (95% CI) 39 mm (31–46) 50 mm (42–58) 211 mm (222 to 21) 0.0339
Oral mucositis pain on VAS, mean (95% CI) 21 mm (15–27) 36 mm (30–42) 215 mm (223 to 27) 0.0004
Pharyngeal mucositis pain on VAS (95% CI) 37 mm (29–45) 48 mm (40–56) 211 mm (222 to 0) 0.0452
* In the Lozenge group (values from the control group are derived from scoring done every 2 hours).
† In oral cavity or pharynx (whichever was higher).
‡ To the nearest whole number (211.63 to 2 decimal places).
CI, confidence interval; VAS, visual analog scale.
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need for improved pain management in patients with head and
neck cancer with oral mucositis.
A randomized double-blind placebo-controlled study on 59
patients with oral mucosal trauma orminor aphthous ulcers found
that a 1% topical lidocaine solution significantly reduced oral pain.
The efficacy of the topical lidocaine solution was not related to the
type of lesion. Although similar results might be expected in
patients with pain due to oral mucositis, while all patients in the
Control group in the present study were offered topical lidocaine
to use after randomization, only 50% of them did so.
Ketamine has been tested in different studies as a topical
analgesic administered as an oral mouthwash. In one study, 8
patients with oral mucositis were treated with ketamine mouth-
wash plus intravenously administered opioids. Five of the 8
patients experienced relief of their mucositis pain, but 4 patients
experienced side effects which were probably related to the
ketamine mouthwash. The side effects included mild confusion,
hallucinations, nausea, and dizziness.17 The theory that in-
flammation causes increased expression of peripheral opioid
receptors has led to studies of the effect of morphine-containing
mouthwashes on oral mucositis pain, but the results are not
consistent.13,18 A systematic review concluded that a 0.2%
morphine mouthwash could be effective in the treatment of oral
mucositis pain in patients with head and neck cancer.18
Tricyclic antidepressants, such as doxepin, have also been
investigated as pain relief, and the above-mentioned systematic
review concluded that a 0.5%doxepinmouthwash could be used
to treat oral mucositis.18 In a study on 51 patients with oral
mucositis due to radiotherapy, pain decreased after pain
management with an oral rinse containing doxepin.5 However,
both morphine and doxepin have systemic effects and some
patients find the mouthwashes unpleasant, as they feel thick and
sticky in themouth and can cause nausea.7 The above-described
studies on systemic drugs show various effects of different kinds
of pain management. However, the tested systemic drugs have
disadvantages in terms of efficacy, tolerability, and/or patient
friendliness. By contrast, topical formulations, such as lozenges,
used as local anesthetics in the oral cavity may possess the
advantages that the concentration of the anesthetic agent will be
high in the oral cavity.2
Figure 3.Mean pain in the oral cavity or pharynx (whichever was higher), scored on a visual analog scale (VAS) 60 minutes after administration of a lozenge in the
Lozenge group (n522) and every 2 hours in the Control group (n516). The error bars show 95 confidence intervals.
Figure 4. Mean pain in (A) the oral cavity and (B) the pharynx, scored on a visual analog scale (VAS) 60 minutes after administration of a lozenge in the Lozenge
group (n522) and every 2 hours in the Control group (n516). The error bars show 95% confidence intervals.
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From a safety perspective, the AEs assessed as related to the
bupivacaine lozenge in the present study were few andmild. Two
patients withdrew because of hyperalgesia. Study personnel
were instructed to be alert to any symptoms indicating systemic
toxicity of bupivacaine, and no such symptoms were reported.
The reporting of AEs focused on possible side effects of the
treatment and did not focus on medical conditions that are
common in the studied patient population, such as nausea and
somnolence. Patients undergoing radiotherapy often experience
dry mouth because of reduced saliva production. In the present
study, this may give rise to a prolonged dissolution of the lozenge
and reduce the effect of bupivacaine by delaying its transport to
the oral cavity and pharynx. The fact that the patients were not
hospitalized but instead used a patient diary at home to register
pain scores as outpatients made it difficult to ensure that they
registered all the required pain scores. However, compliance was
judged to be satisfactory as there were enough pain registrations
to analyze the data. The severity of oral mucositis was assessed
using the World Health Organization scale for oral mucositis.
Unfortunately, the study personnel who did the assessments
focused solely on visible changes in the oral mucosa; they failed
to appreciate that pain, by definition, renders a score of at least 1.
This explains why some patients had a mucositis score of 0 at
randomization despite a baseline pain score of $40 mm.
The pain-relieving effect of bupivacaine lozenges has not been
tested in a blinded placebo-controlled study. It is difficult to
design a blinded placebo-controlled study for several reasons,
not least that it would be difficult to blind patients because the
local anesthetic effect of bupivacaine has been found to be
instant and strong. Therefore, not only is there a risk of
unintended bias in favor of the local anesthetic lozenge, but also
patients will know whether or not they are receiving the active
drug, which makes it very difficult to use a placebo-controlled
design. For these reasons, a placebo group was not considered
appropriate for this study and the most relevant control was
considered to be standard pain treatment.
In conclusion, the tested bupivacaine lozenge was found to be
an effective and safe treatment to reduce pain due to oralmucositis
in patients with head and neck cancer. Further clinical inves-
tigations are warranted to investigate whether the bupivacaine
lozenge may improve pain relief in this difficult-to-treat condition.
Indeed, a multicountry phase III trial is planned. Furthermore, the
effect of the bupivacaine lozenge on other important outcomes
should also be investigated. Such outcomes might include quality
of life, patient nutrition, and the risk of an intermission in cancer
treatment due to inadequate patient nutrition. Finally, because the
bupivacaine lozenge is a noninvasive and patient-friendly way to
alleviate oral mucositis pain, it should be investigated in patients
with other cancer diagnoses who also have oral mucositis, such as
patients with bone marrow transplant.
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